MENU
IRD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Opus Genetics (IRD) Ownership - Who owns Opus Genetics?
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
76.08M
P/E Ratio
N/A
Total Cash
32.43M
Projected Growth
N/A
Total Debt
1M
Revenue
15.42M
Risk (Beta)
0.80
Dividend Yield
N/A
Total Cash/Share
0.54
Total Debt/Equity
N/A
Revenue/Share
0.40 USD as % of share price
Fundamentals
IRD
Capitalization
76.1M
P/E Ratio
N/A
Risk (Beta)
0.80
Dividend Yield
N/A
Total Cash
32.4M
Total Cash/Share
0.54
Total Debt
1M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.40%
Revenue
15.4M
ROE
N/A
Book Value
17.5M
P/B Ratio
4.35
Cash Flow
N/A
Earnings
-1.88
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
6K
Current Ratio
1.90
Current Revenue Per Employee
160111.11
Dividends Per Share - Security
N/A
EBITDA
-61.46M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-139.58
Shares Held By Institutions
15.8M
Shares Outstanding - Current
59.9M
Total Liabilities
21.2M
Total Volume MTD
N/A
Value
N/A
Gain YTD
6.723
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
Profile
Fundamentals
Details